# OnCo record grade-3-net (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/grade-3-net/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "grade-3-net" ;
  schema:name "Grade 3 well-differentiated neuroendocrine tumour"@en ;
  schema:alternateName "NET G3"@en, "Grade 3 NET"@en, "Well-differentiated grade 3 neuroendocrine tumour"@en, "High-grade well-differentiated NET"@en ;
  schema:description "Grade 3 well-differentiated neuroendocrine tumours divide fast enough to be called grade 3 yet still look and behave like their slower relatives rather than like neuroendocrine carcinoma. Recognised as separate since 2017, they keep the somatostatin receptor, respond less well to platinum chemotherapy, and in the NETTER-2 trial were among the first treated with lutetium-177 dotatate up front."@en ;
  schema:url <https://onco.cc/cancers/grade-3-net/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)00701-3>, <https://doi.org/10.1530/ERC-15-0119>, <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  onco:tag "subtype-page", "endocrine" ;
  onco:technologies <https://onco.cc/technologies/sstr-pet/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/pet/>, <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/menin/> ;
  onco:drugs <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/itm-11/>, <https://onco.cc/drugs/octreotide-lanreotide/> ;
  onco:terms <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/terms/tumour-differentiation/>, <https://onco.cc/terms/chromogranin-a/>, <https://onco.cc/terms/prrt-term/> ;
  onco:trials <https://onco.cc/trials/nct03972488/>, <https://onco.cc/trials/nct04919226/>, <https://onco.cc/trials/compete/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-netter-2-lancet-2024/>, <https://onco.cc/key-papers/paper-rindi-common-classification-framework-mod-pathol-2018/>, <https://onco.cc/key-papers/paper-heetfeld-grade-3-net-erc-2015/> ;
  onco:pipeline <https://onco.cc/trials/nct04919226/>, <https://onco.cc/drugs/itm-11/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/ideas/idea-net-dosimetry-prrt/> ;
  onco:standardOfCare <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/terms/tumour-differentiation/>, <https://onco.cc/technologies/sstr-pet/>, <https://onco.cc/technologies/pet/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/trials/nct03972488/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/trials/nct04919226/>, <https://onco.cc/drugs/itm-11/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/tace/>, <https://onco.cc/terms/liver-directed-therapy/> .